Oveporexton

Oveporexton (TAK-861) is an orally active and selective orexin receptor 2 (OX2R) agonist with an EC50 of 2.5 nM. Oveporexton exhibits 3000-fold selectivity for OX2R over OX1R. Oveporexton can be used for the study of hypersomnia disorders including narcolepsy[1][2].

Product Specifications

CAS Number

[2460722-04-5]

Product Name Alternative

TAK-861

UNSPSC

12352101

Target

Orexin Receptor (OX Receptor)

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/oveporexton.html

Purity

99.68

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

CC(C)(O)C(N(CC(F)([C@@H]1NS(CC)(=O)=O)F)[C@H]1CC2=C(C(C3=CC(F)=CC(F)=C3)=CC=C2)F)=O

Molecular Formula

C23H25F5N2O4S

Molecular Weight

520.51

References & Citations

[1]International Nonproprietary Names for Pharmaceutical Substances (INN) . WHO Drug Information, Vol. 38, No. 2, 2024.|[2]Mitsukawa K, et al. TAK-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models. Sci Rep. 2024 Sep 6;14 (1) :20838.